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Abstract
Background: Improving upper limb (UL) motor recovery after stroke represents a major clinical and scientific goal.
We aim to complete three systematic reviews to estimate the (1) association between time to start of UL therapy
and motor recovery, (2) relative efficacy of different UL therapy approaches post-stroke and (3) cost-effectiveness of
UL therapy interventions.
Methods: We have designed a systematic review protocol to address three systematic review questions that were
each registered with PROSPERO. The search will be conducted in MEDLINE, EMBASE, and Cochrane Controlled
Register of Trials. We will include randomised controlled trials, non-randomised clinical trials, before-after studies
and observational studies of adult stroke survivors with an average stroke onset < 6 months, undergoing hospital-
based therapy to improve UL function. Eligible interventions will aim to promote UL functional recovery. Two
reviewers will independently screen, select and extract data. Study risk of bias will be appraised using appropriate
tools. Clinical measures of motor recovery will be investigated (primary measure Fugl Meyer UL assessment), as well
as measures of health-related quality of life (primary measure EQ-5D) and all cost-effectiveness analyses completed.
Secondary outcomes include therapy dose (minutes, weeks, repetitions as available) and safety (i.e. adverse events,
serious adverse events). A narrative synthesis will describe quality and content of the evidence. If feasible, we will
conduct random effects meta-analyses where appropriate.
Discussion: We anticipate the findings of this review will increase our understanding of UL therapy and inform
the generation of novel, data-driven hypotheses for future UL therapy research post-stroke.
Systematic review registration: PROSPERO, http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD4201
8019367, http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018111629, http://www.crd.york.ac.uk/
PROSPERO/display_record.php?ID=CRD42018111628.
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Background
Up to 80% of stroke survivors have upper limb impair-
ment early after stroke [1–3], and few demonstrate
complete functional recovery at 6 months post-stroke
[1, 4]. Upper limb rehabilitation trials designed to
improve recovery rates have been largely unsuccessful.
As a result, the burden of upper limb impairment after
stroke remains high [5]. Therefore, understanding how
to improve the potential for recovery of upper limb
function remains a major scientific, clinical and patient
priority [6, 7].
Why has it proved difficult to improve upper limb
recovery after stroke? Upper limb therapy provided
clinically is described as too little, too late in the recov-
ery timeline [8]. Recent high-profile clinical trials of
upper limb rehabilitation have evaluated relatively low
amounts of therapy (13 to 36 h total or ~ 30 min/day),
e.g. [9, 10] and/or enrolled patients relatively late post-
stroke (i.e. > 6 months post-stroke), e.g. [11]. It remains
unclear whether these trials were equivocal because the
therapy was ineffective in terms of how much, when or
what was delivered. Several syntheses have highlighted
the importance of how much therapy; defining 30 min/
day as too low [12], and 2 h per day as an emerging ther-
apy threshold [13]. To date, no systematic review has ex-
amined the impact of the timing after stroke when
rehabilitation is delivered.
Current clinical practice guidelines recommend that
stroke patients start therapy as soon as possible post-
stroke [14]. The rationale for early upper limb therapy
post-stroke is supported by robust preclinical (animal)
evidence, where it is well established that there is a
sensitive window of heightened plasticity starting around
5 days after ischaemic stroke [15, 16]. In rodents, upper
limb reaching therapy that is commenced at the beginning
of the sensitive window capitalises on the injury-induced
plasticity environment to produce gains in reaching that
are quantitatively and qualitatively superior to those
achieved when therapy of the same dose and duration is
started later (around 14 and 30 days post-stroke) [15]. This
underpins the rationale that timing of therapy is critically
important. In humans, the post-stroke sensitive window is
proposed to begin within the first 10 days post-stroke
[17] and to extend out to 3 and even 6 months post-
stroke [1, 4, 18]. The wide sensitive window of 6
months post-stroke needs to be better understood to
guide recommendations around the critical time win-
dow to deliver upper limb therapy. A handful of upper
limb trials have commenced training ≤ 10 days post-
stroke [10, 19]. None have directly compared the effects
of starting training early compared to a later time point.
This is a major gap, which can be probed by looking at
the functional gains demonstrated in previous upper
limb studies that have started therapy and documented
outcomes within the potential sensitive window, the
first 6 months post-stroke.
The majority of completed upper limb therapy trials
have tested what therapy approach to provide. Despite
this, the ideal upper limb therapy intervention(s) that can
improve recovery after stroke remains largely unknown.
Previous Cochrane systematic reviews of specific therapy
approaches have demonstrated an evidence gap, which
highlights limited and/or insufficient evidence for upper
limb therapy approaches that span repetitive task training
[20], constraint-induced movement therapy [21], electro-
mechanical and robot-assisted therapy [22] and hands-on-
therapy interventions [23]. No systematic review has
compared the relative benefit of different treatment
approaches tested within clinical trials. While a previous re-
view provided a summary of individual therapy approaches
that started early post-stroke [24], the authors did not com-
pare outcomes across therapy approaches. Direct compari-
son between different therapy approaches is also seldom
performed in a single study due to sample size and cost
constraints. Completing a review that directly compares
different intervention approaches may help to establish the
relative efficacy of each approach, as well as a potential
hierarchy of treatment approaches to target in future trials.
The amount of upper limb therapy provided after stroke
is currently pragmatic (i.e. based on available resources
and what can be comfortably delivered within existing
health services) rather than what might work (i.e. aspir-
ational to match best scientific evidence). Delivery of more
therapy is considered to be cost-ineffective (e.g. staffing,
environment). However, consideration of the health
economic arguments for optimum upper limb therapy is
rarely mounted but are warranted to inform best clinical
practice and policy decisions.
To address these gaps, we aim to identify relevant upper
limb therapy studies that aim to improve functional recov-
ery post-stroke and include participants of an average
stroke onset < 6months who are undergoing hospital-
based therapy. We have designed a systematic review
protocol to address three research questions that have
been prospectively registered with PROSPERO. Systematic
reviews are resource- and time-intensive, using data from
a single search strategy to inform multiple questions is
one way to mitigate such issues. We plan to address the
following study objectives:
1. Estimate the association between time to start
upper limb therapy and outcome, taking into
consideration dose of therapy;
2. Estimate the relative efficacy of different upper
limb therapy approaches post-stroke, taking into
consideration time to start and dose of therapy; and
3. Estimate the cost-effectiveness of upper limb
therapy interventions.
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Methods and design
The present protocol is reported in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocols (PRISMA-P) statement [25–27]
(see PRISMA-P checklist in Additional file 1). This proto-
col covers three research questions that will be answered
from one systematic search strategy. All research questions
have been prospectively registered on the International
Prospective Register of Systematic Reviews (PROSPERO):
timing (registration number, CRD42018019367), therapy
efficacy (registration number, CRD42018111629) and cost-
effectiveness (registration number, CRD42018111628).
Search strategy for identification of relevant studies
Electronic searches will be conducted in MEDLINE (via
Ovid), EMBASE (via Ovid) and Cochrane Controlled
Register of Trials (CENTRAL). Hand searches of reference
lists of included studies or identified relevant reviews will
be employed. The search strategy will include terms
related to stroke, upper limb function and movement, and
therapy (see Additional file 1 for MEDLINE/EMBASE,
which was adapted for CENTRAL). The only search strat-
egy limit is ‘human’. Language limits of English, Dutch,
French, German will be applied when screening studies.
Eligibility
Studies will be selected according to the criterion
outlined below.
Types of studies
We will select randomised controlled trials (RCTs),
including cluster RCTs, controlled (non-randomised)
clinical trials or cluster trials, before-after studies, and
observational studies (prospective and retrospective
cohort studies, case-control or nested case-control stud-
ies) which have a minimum of two waves of assessment,
i.e. pre/baseline and post-intervention/follow up. We will
exclude cross-sectional studies, case series, case reports,
qualitative studies, surveys, protocols papers, conference
proceedings and reviews. Data from any study design will
be included in the timing systematic review; however, only
RCTs will be included in the therapy efficacy. The cost-
effectiveness systematic review will include studies report-
ing full economic evaluations using cost-effectiveness
and/or cost-utility analysis methods incorporating both
studies conducted alongside RCTs and health economic
model-based analyses (e.g. deterministic decision analysis,
Markov models, populated with data from the literature).
Participants
Studies that include adults (≥18 years) with a diagnosis
of stroke (ischaemic or haemorrhagic, or at minimum
50% of the sample), average stroke onset < 6 months and
undergoing hospital-based in- or out-patient therapy will
be included.
Interventions
All studies of upper limb therapy (experimental or usual
care intervention) with the aim to improve function will
be included. Examples include bilateral arm training, bio-
feedback, Bobath approach, constraint-induced movement
therapy, electrical stimulation, hands-on therapy (manual
therapy techniques), repetitive task training, robotics,
strength training, task-specific training, virtual reality,
standard therapy [28]. As this review centres around upper
limb motor therapy only, we will exclude
 Use pharmacological (e.g. recovery-promoting
drugs), complimentary (e.g. acupuncture), non-
invasive brain stimulation or priming intervention(s)
(e.g. transcranial magnetic stimulation) in combination
with or without therapy
 Have a primary focus to reduce secondary
impairments, e.g. pain, contracture, spasticity,
subluxation
 Focus on general motor recovery, e.g. activities
of daily living
 Focus on non-motor impairments, e.g. sensory,
hemispatial neglect with or without motor practice
 Do not include any upper limb therapy, e.g. mental/
motor imagery alone
Comparisons or control
No restrictions will be made on the comparison or control
group (e.g. attention control groups and active compari-
sons will be included).
Outcome measures
All clinical measures used to document upper limb
recovery (change) [17] across two assessment time
points, e.g. pre to post-intervention will be explored, as
well as follow up if available to provide information
about the sustainability of recovery gains. For the review
of timing and efficacy, the clinical outcome that is
considered to best reflect recovery of upper limb impair-
ment is the Fugl Meyer Upper Limb (FMUL) [29]. This
measure has been recommended by the international
Stroke Rehabilitation and Recovery Roundtable as a core
data element [29]. As this recommendation was made in
2017, many studies may report other measures. This
includes measures of upper limb activity, such as Action
Research Arm Test (ARAT), Box and Block Test (BBT),
Wolf Motor Function Test (WMFT), Nine-Hole Peg
Test (9HPT) and Motor Assessment Scale (MAS) [13].
Where multiple measures are published, the Fugl Meyer
will be prioritised over all other measures (primary out-
come), followed by timed measures (e.g. Box and Block
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Test) over observational measures (e.g. MAS). Timed
measures will be prioritised over observational (or qual-
ity of movement) measures as they reduce examiner
bias. Secondary outcomes of therapy dose (i.e. minutes,
weeks, repetitions as available) and safety (i.e. reported
adverse events and serious adverse events) will be con-
sidered (see data extraction for more details).
We will explore change in health-related quality of
life within the cost-effectiveness review. We will ex-
tract any generic- or condition-specific preference or
non-preference-based measures of health-related qual-
ity of life. Where multiple measures are published, we
will prioritise incremental change in health-related
quality of life measured using EuroQol (EQ-5D) [30,
31]. EQ-5D is our top priority as it is the recom-
mended core data element from the International
Stroke Rehabilitation and Recovery Roundtable and is
most widely used in clinical research [29].
Screening of studies
All studies identified by the search strategy will be
uploaded to Covidence (https://www.covidence.org/
[32]) and duplicates removed. Two authors (KH/SK)
will screen studies for eligibility based on title and
abstract using predetermined criteria (see Table 1 for
summary). Full text for all remaining studies will be
retrieved and reviewed independently (KH/SK).
Reports from the same study population will be
linked to ensure that data from a particular popula-
tion is only included once in analysis. Authors of
studies may be contacted to collect data that is miss-
ing or to clarify details of the study to ensure appro-
priate study inclusion (e.g. regarding post-stroke time
to recruitment). If a disagreement regarding eligibility
occurs, it will be resolved by discussion and review of
criteria amongst KH/SK. If not resolved, a third re-
viewer (one of NL or NW) will be involved to achieve
a consensus. If still not resolved, a further two
reviewers (two of JB/VT/DC) will be involved. If no
consensus is reached, all reviewers will discuss the
article, and if no consensus is achieved, it will be
documented in the review. The results of the screen-
ing process will be provided in detail using a
PRISMA study flow chart.
Data extraction
Two independent reviewers (of KH/TK/LJ/NL) will
extract data using a predetermined data collection form.
If queries or discrepancies regarding data extraction
occur, these will be resolved by discussion between re-
viewers. If not resolved, an additional reviewer will ex-
tract the data (of VT/GC/AB). If no consensus is
achieved, our statistician (LC) will review the paper and
make a final verdict. The data extraction form will rec-
ord information regarding the following:
1. Study details, i.e. authors, date, location of study
and setting, design and stratification
2. Participants’ information, i.e. number of
participants, age, sex, characteristics of stroke
including type, severity of stroke and upper
limb impairment
3. Clinical outcome measures, i.e. impairment
and activity (per outcome measures)
4. Biomarker measures of the corticospinal tract,
i.e. motor evoked potential status
5. Time post-stroke to recruitment, assessment
and/or intervention start, i.e. days post-stroke
6. Dose of therapy, i.e. minutes, weeks and repetitions
as available. We will extract minutes or repetitions
per session, per day and total minutes and
repetitions. Where both active dose and total
dose (active and rest) are provided, both will
be extracted and synthesised separately.
7. Schedule of therapy, i.e. frequency of sessions,
weeks of therapy
Table 1 Eligibility criteria
Inclusion Exclusion
Adults (>17 years) with a diagnosis of stroke (ischaemic or haemorrhagic)
and average stroke onset <6 months (or at least 50% of the sample has
diagnosis of stroke within the time frame) undergoing hospital based (in
or outpatient) rehabilitation
Pharmacological, complimentary, non-invasive brain stimulation or
priming intervention(s) [delivered in conjunction with motor practice
interventions(s) or alone, ie as a control].
Upper limb therapy (experimental or usual care intervention) with the
aim to improve function
Interventions with the primary focus to reduce secondary impairments
e.g., pain, contracture, spasticity, subluxation; that do not include any
upper limb motor practice e.g., mental/motor imagery practice alone; or
for general motor practice e.g., activities of daily living, or non-motor
impairments e.g., sensory, hemispatial neglect.
A minimum of two waves of motor impairment or activity assessment
i.e., pre and post intervention
Study design of RCT, non RCT, cohort and observational, pre-post single
group. Any control intervention eligible.
Single case, case series, qualitative, surveys, protocols, conference
proceedings, cross-sectional, review, single session intervention
Languages: English, Dutch, French, German (SK/VT/TK fluent).
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8. Content of therapy, i.e. therapy approach,
structure of therapy sessions
9. Safety, i.e. adverse events and serious adverse
events as the total number
10. Economic evaluation, i.e. resource use associated
with the intervention and estimating resources
and costs, study perspective (e.g. health system,
societal), time horizon, discount rate, currency,
price data, assumptions, personal and societal, and
health-related quality of life (per above outcome
measures above), as well as the full economic
evaluations using cost-effectiveness and/or cost-
utility analysis and health economic model-based
analyses
11. Results for clinical measures, i.e. means, standard
deviations, coefficients, p values, effect size,
medians, interquartile ranges
12. Missing/incomplete data to be followed up
The corresponding author of any study with missing
or incomplete data will be contacted for further
information.
Risk of bias
We will use the Cochrane Risk of Bias tool to examine
bias across five domains for randomised controlled trials
[33]. For other designs, we will use the ROBINS-I tool
[34]. Two reviewers (of JB/NW/VT) will use the appro-
priate tool to independently rate each included study. If
queries or discrepancies regarding data extraction occur,
these will be resolved by discussion between reviewers.
If not resolved, a further two authors (GC/AB) will
complete the risk of bias tool. If no consensus is achieved,
our statistician (LC) will review the paper and make a final
verdict.
Strategy for data synthesis
Our systematic review results will be reported by
describing study characteristics, participant characteris-
tics and outcome results. For all outcomes considered,
we will present summary data for each therapy group
and effect estimates and confidence intervals as feasible.
We will also describe our literature search results, as
well as the methodological quality and risk of bias re-
sults using tables, figures and text. Strength of the evi-
dence will be determined using GRADE as appropriate
[35]. We will evaluate whether we have sufficient data to
conduct random effects meta-analysis. We will also en-
sure that the body of literature is sufficiently
homogenous in terms of clinical (e.g. patient characteris-
tics), methodological (e.g. study design) and statistical
(e.g. forest plot consistency) characteristics. For example,
we will use our clinical insight to assess for clinical het-
erogeneity, methodologists will assess for methodological
heterogeneity, and statistical heterogeneity will be calcu-
lated. We will try to explain potential heterogeneity via
subgroup analysis and meta-regression analysis, as de-
scribed below.
Timing
We will explore the distribution of the data and allocate
cohorts to timing categories based on mean/median group
values. Our framework for time window classification is
the recent Stroke Rehabilitation and Recovery Roundtable
recommendations, as the chosen time-windows are linked
to our current understanding of the neurobiology of
recovery [17]:
 Hyperacute, ≤ 24 h post-stroke
 Acute, > 24 h but ≤ 7 days post-stroke
 Early subacute, > 7 days but ≤ 3 months post-stroke
 Late subacute, > 3 months but ≤ 6months post-stroke
If data are appropriate for quantitative synthesis, we
will pool effects across studies within each time window
(subgroups) using random effects meta-analysis models
to report standardised mean difference (95% CI). This
will accommodate both our primary outcome of interest
(Fugl Meyer), as well as other outcome measures that
may be used. Standard deviation to inform the analysis
will be extracted from text, calculated from available
data in text or by contacting the primary author. We will
also calculate measures of heterogeneity and consistency
as appropriate. If data are appropriate, the association of
timing with estimated effects on functional outcomes
using a random effects meta-regression analyses and a
sensitivity analysis of studies assessed as low risk of bias
will be completed.
Clinical efficacy
We will allocate studies to therapy approaches consist-
ent with a recent Cochrane review [28], with inappropri-
ate categories removed consistent with our eligibility
criteria, e.g. recovery-promoting drugs and non-invasive
brain stimulation. Intervention approach categories of
interest are bilateral arm training, biofeedback, Bobath
approach, constraint-induced movement therapy, elec-
trical stimulation, hands-on therapy (manual therapy
techniques), repetitive task training, robotics, strength
training, task-specific training, virtual reality, standard
therapy category (i.e. control group) and others. If data
are appropriate, we will attempt conducting a network
meta-analysis (NMA). This analysis is particularly useful
when there is a lack of head-to-head studies or when
both relevant head-to-head and standard treatment-
controlled studies exist. The network meta-analysis
approach allows ranking of interventions. Key
considerations that will be evaluated on completion of
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data extraction for NMA will be handling of multi-arm
trials, variance structures and assessment of fit and
consistency. This analysis will be conducted in Stata
and/or R, and median rankings (or point estimates) will
be calculated using a random effects model that makes
use of all available direct and indirect data. The degree
of uncertainty for all point estimates will be reported as
95% confidence/credible intervals (CIs).
Cost-effectiveness
We will use the CHEERS statement to examine the
reporting quality of the identified economic evaluations
[36]. If possible, we will pool effects across studies using
random effects meta-analysis models as appropriate for
specific outcomes and the data available for analysis. Key
considerations for pooled analysis will be the number of
studies identified, their quality and consistency of cost
and outcomes.
Ethics, amendments and dissemination
We will use only secondary de-identified data to address
the three research questions; therefore, ethics approval is
not required. Any protocol amendments will be tracked
against our PROSPERO record and outlined in the final
publication. The findings of the three reviews will be
disseminated through presentation at appropriate
forums and conferences. The completed reviews will be
submitted for publication in peer-reviewed journals.
Findings will be translated to inform the development of
upper limb therapy protocols that will be tested in future
clinical trials.
Discussion
The described protocol represents a novel approach to
undertaking a systematic review. By using a broad search
strategy, we can address several critical research ques-
tions simultaneously. An appropriately designed search
strategy is likely to yield large volumes of data and will
require considerable time to determine eligibility and ex-
tract relevant data. The proposed approach to complet-
ing a systematic review will minimise research waste,
which is critical given the time taken to complete sys-
tematic reviews. Furthermore, the outputs will synthesise
past research to generate novel, data-driven hypotheses
for future research that aims to define a new therapy
pathway(s) to promote upper limb recovery. While each
review may yield the answers to our questions, there is
the likelihood that they will demonstrate that we do not
yet have the appropriate data to allow clinicians to make
evidence-based decisions about hospital-based upper
limb therapy within the first 6 months post-stroke. This
finding is as important as yielding all the answers and
will form the foundation for designing studies that can
answer these important research questions in stroke re-
habilitation and recovery.
The methods and results of our systematic reviews
will be reported following the PRISMA statement and
their relevant extensions [25–27]. While this review
will be completed with the upmost of care, there are
some limitations. It is well documented that a large
range of upper limb outcome measures are reported
in research [37] which prevents individual patient
data analysis. Further, there may be missing data that
will impact data collation, comparison across studies
and pooled analyses. We acknowledge language
restrictions beyond English, German, French and
Dutch. We do not intend to hand-search conference
proceedings. In addition, the observational nature of
the subgroup analyses means they should be inter-
preted with caution, as it is known that subgroup
analyses can be less highly powered than analyses for
main effects.
Additional file
Additional file 1: Search strategy. (DOCX 14 kb)
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